Optos

What Optos does

Optos plc is a medical device company specializing in ultra-widefield (UWF) retinal imaging technology, founded in 1992 and headquartered in Dunfermline, Scotland, with a US subsidiary in Marlborough, Massachusetts. The company designs and manufactures scanning laser ophthalmoscope (SLO) systems, with flagship products Silverstone, MonacoPro (launched March 2025), California, and Daytona. Optos' core differentiator is proprietary 200° single-capture ultra-widefield retinal imaging — the only such capability globally — paired with swept-source optical coherence tomography (OCT) and a broad image-modality portfolio (color rg/rgb, red-free, blue and green autofluorescence, fluorescein angiography, indocyanine-green angiography). The optomap Recognizing Pathology software provides searchable clinical decision support across these modalities.

Optos sells its capital imaging equipment through a direct enterprise sales force and an authorized global distributor network, targeting ophthalmology practices, hospitals, optometry practices, and academic research institutions. The company has installed more than 30,000 devices worldwide and supports the installed base with recurring equipment service programs and cloud-based PACS/OptosAdvance software subscriptions. Marketing and lead generation are conducted via industry conferences (ARVO, AAO, Euretina, AOA, Vision Expo), content marketing through clinical case studies and webinars, email communications, and an active social media presence.

Since 2015, Optos has operated as a wholly-owned subsidiary of Nikon Corporation, with 501-1,000 employees globally. The company is privately held post-Nikon acquisition, incorporated in Scotland (registered number SC139953), and compliant with UK GDPR, EU GDPR, and CCPA data-protection regimes. Its addressable widefield imaging systems market is reported at $744.2M in 2025 with growth forecasts ranging from 5.5% CAGR (to $1.27B by 2035) to 11.9% CAGR (to $1.84B by 2030), driven by rising retinal disease prevalence, AI integration, and demand for portable and data-managed imaging solutions.

Name

Optos

Legal name

Optos plc

Website

https://optos.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Optos plc, a Nikon-owned medical device company, develops ultra-widefield retinal imaging systems (SLO and OCT) — the only 200° single-capture platform globally — sold to ophthalmology and optometry practices, hospitals, and research institutions across a 30,000+ device installed base.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostic Imaging Equipment

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

Keywords

• Retinal imaging devices
• Ultra-widefield imaging
• Ophthalmic diagnostics
• Scanning laser ophthalmoscopy
• Optical coherence tomography

Headquarters

HQ city

Dunfermline

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Imaging Device Sales: Sale of ultra-widefield retinal imaging devices (Silverstone, MonacoPro, California, Daytona) to healthcare providers including ophthalmology practices, hospitals, and eye care clinics. Devices are sold as capital equipment with associated installation and training services.
2. Equipment Service Programs: Ongoing service and maintenance contracts for installed devices, providing revenue from the existing installed base of 30,000+ devices globally.
3. Software and PACS Solutions: Picture Archiving and Communication Software solutions for managing and viewing retinal images, including cloud-based platforms like OptosAdvance.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Optos manufactures and sells ultra-widefield (UWF) retinal imaging devices — including the Silverstone, MonacoPro, California, and Daytona product families — that enable ophthalmologists, optometrists, and eye-care clinics to capture wide-field, single-shot images of the retina for the diagnosis and management of retinal disease. The devices combine proprietary Scanning Laser Ophthalmoscopy (SLO) and Optical Coherence Tomography (OCT) technologies and are sold alongside associated software and service contracts.

Product overview

Optos offers a portfolio of ultra-widefield (UWF) retinal imaging devices led by Silverstone (flagship with full modality suite including swept-source OCT), MonacoPro (advanced UWF SLO combined with OCT, launched March 2025), California, and Daytona. The core technology platform centers on the optomap imaging system that captures 200° single-capture retinal images. Supporting the devices are multiple image modality options including color rg/rgb, red-free, blue and green autofluorescence, fluorescein angiography (FA), indocyanine-green angiography (ICG), and swept-source OCT. Additional offerings include software tools like optomap Recognizing Pathology for clinical decision support and equipment service programs.

Differentiator

Problem solved

Functional benefit

Brands

• Silverstone: Advanced ultra-widefield retinal imaging device
• MonacoPro
• California
• Daytona

Products and services

• Silverstone

Quantifiable outcome

• 30,000+ devices installed globally
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nidek: Nidek manufactures OCT and fundus imaging devices (e.g., Mirante) used by the same ophthalmology and optometry customers that buy Optos systems. Direct overlap in retinal and multimodal imaging for clinical diagnostics.
• Topcon Healthcare: Topcon's Maestro, Triton, and 3D-OCT systems directly compete with Optos in optometry and ophthalmology channels. Topcon also bundles its imaging hardware with software-driven screening and data-management offerings, putting it in close competition with the OptosAdvance platform.
• Optovue (Visionix / Bolé): Optovue pioneered Fourier-domain OCT for ophthalmology and now operates within the Visionix/Bolé group, directly competing in OCT and anterior/posterior segment imaging. It sells into the same optometry and ophthalmology channel as Optos.
• Heidelberg Engineering: Heidelberg Engineering's Spectralis OCT platform is the most established competitor in ophthalmic imaging and directly competes with Optos' MonacoPro/Silverstone in ophthalmology and optometry practices. Both companies sell premium multi-modality imaging devices to retinal specialists.
• iCare (Revenio Group): iCare offers a portfolio of ophthalmic diagnostic imaging and tonometry devices used in optometry and ophthalmology. Its retinal imaging products overlap with Optos in primary eye care and screening workflows.
• Canon Medical Systems (Ophthalmic): Canon's ophthalmic division offers OCT and retinal cameras (e.g., Xephilio OCT) that compete with Optos in hospitals and specialty clinics. Canon leverages precision-optics heritage akin to Nikon's, with comparable imaging capabilities in the OCT/retinal space.

Broad incumbents

• Alcon: Alcon is one of the largest diversified ophthalmic device companies, with a surgical and vision-care portfolio that includes diagnostic imaging adjacent to Optos' territory. While not a direct UWF imaging competitor, it shapes the broader ophthalmic device market and channel relationships.
• Carl Zeiss Meditec: Zeiss offers the Cirrus HD-OCT and other ophthalmic diagnostic devices, competing head-on with Optos in retinal imaging while also operating a much broader surgical ophthalmology portfolio. Overlapping customer base in hospitals and specialty eye-care practices.
• Bausch + Lomb: Bausch + Lomb operates across ophthalmic pharmaceuticals, surgical, and vision care, with diagnostic device offerings that compete for ophthalmology practice budgets alongside Optos. Its broader portfolio gives it cross-sell advantages in eye-care channels.

Emerging players

• Eyenuk: Eyenuk is an AI-driven retinal screening company whose EyeArt system is FDA-cleared for autonomous diabetic retinopathy detection. It represents a software-first threat to traditional imaging hardware leaders like Optos by shifting value toward AI diagnostics from lower-cost fundus cameras.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/optosma
• YouTubeyoutube.com/user/OptosPlc
• Facebookfacebook.com/optomap
• LinkedInlinkedin.com/company/optos
• Instagraminstagram.com/optomap

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optos